The stigma of undergoing a "procedure" to look better or younger has eased to some extent, especially with the availability of therapeutics and other non-surgical treatments, but while many patients have indicated an interest in medical aesthetics, only a fraction have dipped their toes in the water.
Aesthetics Market Review
This article is the second in a series of three about the medical aesthetics market. Part 1 covered the key players
Biopharmaceutical companies with US FDA-approved neurotoxins, such as Allergan PLC's wrinkle-reducer Botox Cosmetic (onabotulinumtoxinA) and Merz's competing Xeomin (incobotulinumtoxinA), are investing significantly in "consumer activation," including advertising campaigns with celebrity spokesmodels and unbranded online initiatives to guide
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
